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BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) tumour expression may provide added value to human equilibrative
nucleoside transporter-1 (hENT1) tumour expression in predicting survival following pyrimidine-based adjuvant chemotherapy.
METHODS: DPD and hENT1 immunohistochemistry and scoring was completed on tumour cores from 238 patients with pancreatic
cancer in the ESPAC-3(v2) trial, randomised to either postoperative gemcitabine or 5-ﬂuorouracil/folinic acid (5FU/FA).
RESULTS: DPD tumour expression was associated with reduced overall survival (hazard ratio, HR = 1.73 [95% conﬁdence interval,
CI = 1.21–2.49], p = 0.003). This was signiﬁcant in the 5FU/FA arm (HR = 2.07 [95% CI = 1.22–3.53], p = 0.007), but not in the
gemcitabine arm (HR = 1.47 [0.91–3.37], p = 0.119). High hENT1 tumour expression was associated with increased survival in
gemcitabine treated (HR = 0.56 [0.38–0.82], p = 0.003) but not in 5FU/FA treated patients (HR = 1.19 [0.80–1.78], p = 0.390). In
patients with low hENT1 tumour expression, high DPD tumour expression was associated with a worse median [95% CI] survival in
the 5FU/FA arm (9.7 [5.3–30.4] vs 29.2 [19.5–41.9] months, p = 0.002) but not in the gemcitabine arm (14.0 [9.1–15.7] vs. 18.0
[7.6–15.3] months, p = 1.000). The interaction of treatment arm and DPD expression was not signiﬁcant (p = 0.303), but the
interaction of treatment arm and hENT1 expression was (p = 0.009).
CONCLUSION: DPD tumour expression was a negative prognostic biomarker. Together with tumour expression of hENT1, DPD
tumour expression deﬁned patient subgroups that might beneﬁt from either postoperative 5FU/FA or gemcitabine.
British Journal of Cancer (2018) 118:947–954; https://doi.org/10.1038/s41416-018-0004-2
INTRODUCTION
Pancreatic ductal adenocarcinoma is one of the leading causes of
cancer-related death worldwide and will shortly overtake breast
cancer as the second leading cause of cancer death in the USA,
with limited survival following primary treatment.1–3 Following
multicentre studies by the European Study Group for Pancreatic
Cancer (ESPAC) and others, it is now clear that adjuvant
chemotherapy with either 5-ﬂuorouracil with folinic acid (5FU/
FA), gemcitabine monotherapy, or gemcitabine plus capecitabine
(a 5FU prodrug) for 6 months following pancreatic resection
increases long-term survival.4–10 Adjuvant S-1, an orally active
drug containing tegafur (another 5FU prodrug), has also improved
survival in patients from Japan.11
Although both 5FU/FA and gemcitabine are efﬁcient at the
cohort level, speciﬁc individuals may beneﬁt more from either
gemcitabine or 5FU/FA. There are currently no established tools to
select the optimal treatment for the individual patient with
pancreatic cancer. The cellular response to pyrimidine-based
chemotherapy is dependent on a series of proteins involved in the
trans-membrane uptake and metabolism.12,13 Our laboratory has
previously reported that high protein expression of human
equilibrative nucleoside transporter 1 (hENT1) was associated
with improved overall survival of patients in the gemcitabine arm
of the ESPAC-3(v2) trial, but not in the 5FU/FA arm.14 These results
indicated that other markers should be sought to help predict 5FU
activity.
Dihydropyrimidine dehydrogenase (DPD) is an enzyme
encoded by the gene DPYD located on chromosome 1p22,15
which catabolizes 5FU into dihydroﬂuorouracil.16 Metabolites of
5FU interfere with cell function by inhibition of DNA synthesis and
repair, RNA transcription and DNA methylation.16 The main
mechanism of 5FU activation is conversion to ﬂuorodeoxyuridine
via thymidylate phosphorylase and then conversion to ﬂuoro-
deoxyuridine monophosphate (FdUMP) by thymidine kinase.
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FdUMP inhibits thymidylate synthase, which is important for the
folate-homocysteine cycle and purine and pyrimidine synthesis.
Other key metabolites are ﬂuorouridine triphosphate and
ﬂuorodeoxyuridine triphosphate, which are incorporated into
RNA and DNA, respectively. The rate-limiting step of 5FU
catabolism is the conversion of 5FU to dihydroﬂuorouracil by
DPD, which is then converted to ﬂuoro-β-ureidopropionate and
subsequently to ﬂuoro-β-alanine.16 Thus, we could hypothesise
that low intra-tumoural DPD expression would favour the
production of cytotoxic 5FU metabolites and prolong survival.
This hypothesis has received some support from small retro-
spective studies predominantly involving the composite drug S-
1.17–23 Gimeracil, a component of S-1, is an inhibitor of DPD that
maintains a high concentration of 5FU in blood and tumour
tissue.11
In the present study, the expression of intra-tumoural DPD was
analysed in tissue from patients in the ESPAC-3(v2) trial that had
been randomised to 6 months of gemcitabine or 5FU/FA following
pancreatic resection. Our primary objective was to test the
hypothesis that DPD expression status was a speciﬁc marker for
5FU-based chemotherapy. Secondary exploratory objectives
tested whether DPD expression could add to the predictive value
of hENT1 expression in selecting patients for either gemcitabine or
5FU adjuvant therapy.14
MATERIALS AND METHODS
Study design
The translational ESPAC-T studies received ethics committee
approval for the characterization of tumour markers for che-
motherapy from the Liverpool (Adult) Research Ethics Committee
(07/H1005/87). Good Clinical Practice Standard Operating Proce-
dures (SOPs) were employed to minimise study biases with a full
audit trail. The ESPAC-3 trial randomised 551 patients to 5FU/FA
and 537 to gemcitabine (Neoptolemos et al.7)]. This was originally
analysed on an intention-to-treat basis but, for the ESPAC-T study,
patients in the treatment arms were selected for inclusion only if
treatment was actually received. All patients provided written
informed consent. This study was conducted and reported in
accordance with the REMARK criteria.24,25
Tissue microarray (TMA) manufacture
Tissue arrays were manufactured using SOP’s as previously
reported.14 The arrays contained tumour cores from patients
included in the ESPAC-3(v2) trial and randomised to 5FU/FA or
gemcitabine, or from patients from the ESPAC-1/ESPAC-3(v1) trial
randomised to observation only. Cores were taken from tumour
regions identiﬁed by an experienced pancreatic pathologist (FC)
using haematoxylin and eosin (H&E)-stained sections. Tissue
microarrays were prepared with two cores from each block, with
four to eight cores arrayed for each patient. Each of the TMA’s had
two cores from each of 88 patients. For all arrays, control cores,
comprising three cores each of colon, kidney, liver, normal
pancreas, and chronic pancreatitis, were arranged in a fence
around the test samples. Each core on each TMA was coded and
linked separately to trial identiﬁers.
Immunohistochemistry
TMA blocks were cut in 3 µm sections and placed on Superfrost
Ultra Plus® slides (Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA).
Deparafﬁnisation and antigen retrieval were performed with the
PT-Link® system and pH 9.0 target retrieval buffer (Dako, Glostrup,
Denmark). All buffers and reagents were provided in the
EnVisionTM kit (Dako): slides were washed in tris-buffered saline
with 0.05% Tween-20 (TBS-T) before peroxidase blocking for 10
min. Following TBS-T washes, samples were incubated with rabbit-
anti-DPD diluted 1:2000 for 60 min, followed by incubation with
secondary horseradish peroxidase-conjugated antibody for 60
min. Following repeated TBS-T washes, slides were covered in
fresh diaminosobenzidine (DAB) working solution for 10 min in
room temperature. Slides were washed in TBS-T and distilled
water, and counterstained in Haematoxylin Gills III and dehydrated
via a series of ethanol gradients and xylene before being mounted
under cover slips.
Validation and quality assessment of the primary anti-DPD
antibody
The primary antibody (rabbit-anti-DPD, Abcam Ab 134922, Abcam,
Cambridge, UK) was validated in accordance with ESPAC-T
steering committee policy. Western blot and immunocytochem-
istry on lysates and parafﬁn-embedded naive as well as anti-DPD
siRNA-treated cell lines conﬁrmed that the antibody was speciﬁc
and sensitive for the presence or absence of human DPD
(Supplementary Figures 1–3, Online Data). Positive-staining tissue
cores (healthy liver) and negative-staining tissue cores (healthy
colon) were used as internal controls. Negative control slides
underwent identical staining procedures, but with the primary
antibody replaced by antibody dilution buffer only.
Scoring
The DPD expression in tumour cell compartments of all samples
were scored by one experienced pancreas pathologist (FC) and
one trained assistant (EG) according to a 0–3 point system (0 = no
staining, 1 = weak, 2 = moderate, 3 = strong staining, with repre-
sentative images viewed in Supplementary Figures 4A–D). FC and
EG were both blinded to patient ID and clinical data. In general,
the intra-core variability was low, but if staining intensity within
the core was not fully consistent, the most commonly observed
pattern was scored. This means that if a core contained only one
or two cells that were immunopositive, but the predominant
pattern was negative (‘0’), then the core in total was scored ‘0′.
Any disagreement in scoring of the immunohistochemistry was
resolved through discussion and a consensus decision. Each
patient was given a single scoring grade equal to the mean of
cores, rounded to the nearest integer. Since a score = 3 was found
in only three patients in the entire cohort, scores 2–3 were
grouped into the high DPD expressing group, and dichotomous
comparisons were consequently performed with the low DPD
expressing group (scores = 0–1). The previously collected
hENT1 scores for the tumours14 were added to the data set to
investigate a possible relationship with the DPD scores. The DPD
and hENT1 scores were not correlated (Pearson correlation =
−0.01).
Statistical considerations
Survival from the date of randomisation was analysed using
Kaplan–Meier curves, with differences between groups assessed
using the log rank test.26,27 Univariable and multivariable analyses,
using a backwards elimination method, were carried out using Cox
proportional hazards.28 A 2-sided signiﬁcance level of P < 0.05 was
used throughout. If not otherwise stated, 95% conﬁdence intervals
(CI) were presented. To adjust for multiple testing in the combined
DPD and hENT1 expression subgroups, Bonferroni correction was
performed for these analyses. Analyses were carried out using
STATA v14 (StataCorp).
RESULTS
Immunohistochemical staining and scoring
We stained tissue cores from 303 patients: 272 patients
randomised and treated in the chemotherapy arms of the
ESPAC-3(2) trial,7 and 31 patients randomised to observation in
the combined ESPAC-1/ESPAC-3(v1) trials.4–7 Cores from 34
patients from the ESPAC-3(v2) chemotherapy arms and eight
patients from the observational arms contained insufﬁcient tissue
to score, or only severely damaged tissue. Overall cores from 261
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Table 1. Cox proportional hazards univariate analyses of survival by clinical and pathological risk factors, DPD tumour expression (low, score= 0–1;
high, score= 2–3), and hENT1 tumour expression (high vs. low deﬁned by median H-score)
Univariate analysis
Hazard ratio (95% Conﬁdence Interval)
Chemotherapy Total
Characteristic 5-ﬂuorouracil /folinic acid Gemcitabine
Resection margin n= 115 n= 123 n= 238
Negative 1 1 1
Positive 2.13 (1.41–3.12) 1.12 (0.76–1.66) 1.52 (1.15–2.01)
Wald χ2= 12.85, p < 0.001 Wald χ2= 0.34 p= 0.558 Wald χ2= 8.75, p = 0.003
WHO n= 115 n= 123 n= 238
0 1 1 1
1 1.62 (1.07–2.47) 1.46 (0.95–2.24) 1.54 (1.14–2.08)
2 0.97 (0.43–2.21) 1.22 (0.63–2.37) 1.09 (0.64–1.85)
Wald χ2= 5.79, p= 0.055 Wald χ2= 3.01, p= 0.222 Wald χ2= 8.55, p = 0.014
Lymph node status n= 115 n= 123 n= 238
Negative 1 1 1
Positive 3.15 (1.76–5.62) 1.61 (0.95–2.74) 2.24 (1.50–3.33)
Wald χ2= 15.03, p < 0.001 Wald χ2= 3.08, p= 0.079 Wald χ2= 15.82, p < 0.001
Tumour stage n= 114 n= 122 n= 236
1/2 1 1 1
3/4 1.92 (1.19–3.11) 1.47 (0.97–2.23) 1.67 (1.22–2.28)
Wald χ2= 7.16, p = 0.008 Wald χ2= 3.34, p= 0.068 Wald χ2= 10.13, p = 0.002
Tumour grade n= 112 n= 120 n= 232
Well 1 1 1
Moderate 0.58 (0.36–0.94) 0.95 (0.42–2.12) 0.77 (0.47–1.28)
Poor 0.75 (0.39–1.43) 1.25 (0.53–2.94) 1.02 (0.58–1.80)
Wald χ2= 5.17, p= 0.075 Wald χ2= 1.56, p= 0.460 Wald χ2= 3.15 p= 0.207
Local invasion n= 115 n= 122 n= 237
No 1 1 1
Yes 1.30 (0.86–1.97) 1.24 (0.85–1.81) 1.27 (0.96–1.68)
Wald χ2= 1.56, p= 0.211 Wald χ2= 1.20, p= 0.273 Wald χ2= 5.06 p = 0.025
Maximum tumour diameter n= 111 n= 118 n= 229
<30mm 1 1 1
≥30mm 1.28 (0.84–1.95) 1.36 (0.91–2.03) 1.33 (1.00–1.77)
Wald χ2= 1.36, p= 0.244 Wald χ2= 2.25, p= 0.134 Wald χ2= 3.78 p= 0.052
Diabetes mellitus n= 112 n= 121 n= 233
No 1 1 1
Yes 0.96 (0.54–1.69) 0.90 (0.55–1.49) 0.92 (0.64–1.33)
Wald χ2= 0.02, p= 0.875 Wald χ2= 0.20, p= 0.653 Wald χ2= 0.18, p= 0.673
Gender n= 115 n= 123 n= 238
Male 1 1 1
Female 1.19 (0.78–1.81) 1.20 (0.80–1.81) 1.19 (0.89–1.60)
Wald χ2= 0.66, p= 0.418 Wald χ2= 0.76, p= 0.383 Wald χ2= 1.40, p= 0.237
Age, years n= 115 n= 123 n= 238
≥64 1 1 1
<64 1.33 (0.87–2.02) 0.89 (0.60–1.33) 1.07 (0.81–1.42)
Wald χ2= 1.74, p= 0.188 Wald χ2= 0.32, p= 0.570 Wald χ2= 0.23, p= 0.634
Smoking n= 108 n= 113 n= 221
Never smoker 1 1 1
Ex-smoker 0.91 (0.57–1.46) 1.28 (0.82–1.98) 1.08 (0.79–1.49)
Current smoker 0.92 (0.52–1.62) 1.48 (0.77–2.85) 1.13 (0.74–1.73)
Wald χ2= 0.17, p= 0.920 Wald χ2= 1.94, p= 0.380 Wald χ2= 0.42, p= 0.810
DPD expression n= 115 n= 123 n= 238
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(86.14%) patients were scored, including 238 chemotherapy-
treated patients, 115 (20.9% originally randomised) given 5FU/FA
and 123 (20.9% originally randomised) given gemcitabine plus 23
patients randomised to observation. Demographics, shown in
Supplementary Table 1, are similar to those previously reported
for the whole trial population.7,14 DPD expression tumour scores in
relation to clinical and pathological variables are shown in
Supplementary Table 2. Representative images of the different
scores and their respective frequencies in the entire population
are presented in Supplementary Figure 4.
Cox regression univariate analyses
Cox proportional hazards univariate analyses of survival by
clinico-pathologic risk factors, DPD tumour expression (low
expression, score = 0–1; high expression, score = 2–3) and hENT1
expression (low/high, cutoff deﬁned by the median H-score) by
treatment arm and collectively are shown in Table 1. Signiﬁcant
prognostic factors for the entire chemotherapy-treated population
(both gemcitabine and 5FU/FA) were resection margin status,
WHO performance status, lymph node status, tumour stage,
tumour invasion into nearby organs, and DPD expression. High
DPD expression was associated with reduced survival (hazard ratio
[HR] 1.73, 95% CI: 1.21–2.49, p = 0.003). This difference was
signiﬁcant in the 5FU/FA arm (HR: 2.07, 95% CI: 1.22–3.53, p =
0.007), but not in the gemcitabine arm (HR: 1.47, 95% CI:
0.91–2.37, p = 0.119). Tumour expression of DPD was not
signiﬁcantly associated with any of the other clinical or
pathological factors analysed (Supplementary Table 2). Tumour
expression of hENT1 was not prognostic for the whole
chemotherapy cohort (HR: 0.84, 95% CI: 0.63–1.12, p = 0.230),
but was predictive for improved survival with gemcitabine (HR:
0.56, 95% CI: 0.38–0.82, p = 0.003) but not for 5FU/FA (HR: 1.19,
95% CI: 0.80–1.78, p = 0.390).
Multivariate analyses of prognostic factors in the respective
treatment arms
A multivariate Cox regression model for prognosis showed that
treatment arm was not signiﬁcant (p = 0.138), whilst DPD
expression was (p = 0.003), and hENT1 expression was not
signiﬁcant (p = 0.327). The interaction of treatment arm and DPD
expression was not signiﬁcant (p = 0.303), but the interaction of
treatment arm and hENT1 expression was (p = 0.009).
Furthermore, multivariate analysis revealed that DPD expression
status, along resection margin status, WHO performance status,
and lymph node involvement were independent prognostic
factors in the 5FU/FA treated subgroup but not the
gemcitabine-treated group (Table 2). High DPD expression was
signiﬁcantly associated with survival in the 5-FU/FA treated group
(HR 3.30; 95% CI 1.89–5.77; p < 0.001) but not in the gemcitabine-
treated group (HR 1.62; 95% CI 0.97–2.69; p = 0.065).
Table 1 continued
Univariate analysis
Hazard ratio (95% Conﬁdence Interval)
Chemotherapy Total
Characteristic 5-ﬂuorouracil /folinic acid Gemcitabine
Low 1 1 1
High 2.07 (1.22–3.53) 1.47 (0.91–2.37) 1.73 (1.21–2.49)
Wald χ2= 7.22, p = 0.007 Wald χ2= 2.43, p= 0.119 Wald χ2= 8.86, p = 0.003
hENT1 expression n= 113 n= 118 n= 231
Low 1 1 1
High 1.19 (0.80–1.78) 0.56 (0.38–0.82) 0.84 (0.63–1.12)
Wald χ2= 0.74, p= 0.390 Wald χ2= 8.98, p = 0.003 Wald χ2= 1.44, p= 0.230
Data in bold indicate signiﬁcant relationships.
Table 2. Multivariate analyses for survival of clinical and pathological risk factors and DPD tumour expression in 5-ﬂuorouracil with folinic acid and
gemcitabine-treated arms
Multivariate Analysis
Variable 5-ﬂuorouracil /folinic acid (n= 115) Gemcitabine (n= 123)
HR (95% CI) Wald χ2 p HR (95% CI) Wald χ2 p
Country 6.55 0.050 Not included
Resection margin Negative 1 7.75 0.005 1 0.30 0.585
Positive 1.95 (1.22–3.11) 1.12 (0.75–1.67)
WHO 0 1 8.47 0.013 1 3.38 0.184
1 2.15 (1.28–3.60) 1.47 (0.95–2.27)
2 1.72 (0.76–3.89) 1.06 (0.53–2.13)
Lymph node status Negative 1 8.94 0.003 1 3.76 0.053
Positive 2.88 (1.44–5.77) 1.71 (0.99–2.95)
DPD expression 0/1 1 17.71 <0.001 1 3.41 0.065
2/3 3.30 (1.89–5.77) 1.62 (0.97–2.69)
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Integrating DPD and hENT1 as predictive biomarkers for adjuvant
chemotherapy
In the combined chemotherapy-treated group (5FU/FA and
gemcitabine), the median (95% CI) overall survival time was 25.6
(21.2–28.6) months in patients with low DPD tumour expression
and 14.3 (10.0–21.1) months in those with high DPD expression
(χ2LR,1 df = 10.4, p = 0.001, Fig. 1). This difference remained statisti-
cally signiﬁcant in the 5-FU/FA arm treated subgroup, where
median (95% CI) overall survival was 26.4 (21.8–30.1) months with
low DPD tumour expression and 10.0 (5.8–22.6) months in those
with high DPD expression (χ2LR, 1 df = 9.56, p = 0.002). Overall
median (95% CI) survival in gemcitabine-treated patients was not
signiﬁcantly different according to DPD status (24.4 (17.1–28.7)
months in those with low DPD tumour expression and 15.7
(13.9–23.6) months in those with high DPD expression (χ2LR, 1 df =
2.33, p = 0.127). The small population of patients randomised to
observation was separately analysed. Patients with low DPD
expression (n = 20) had an overall median (95% CI) of 17.5
(6.8–34.3) months compared to 4.6 (3.2–31.6) months in those
with high DPD (n = 3) expression (Fig. 1). Due to the low numbers
in this subset of patients, no p values were calculated and further
statistical calculations or subdivisions were not performed.
Patients with high and low hENT1 tumour expression were
subdivided according to high and low DPD tumour expression
(Table 3 and Supplementary Figure 5). As we have previously
reported, high hENT1 expression was associated with more
favourable survival in gemcitabine-treated patients.14 We found
no evidence for an additional prognostic value of DPD when
added to hENT1 status in gemcitabine-treated patients. The
median (95% CI) overall survival of patients treated with
gemcitabine with high hENT1 intra-tumoural expression and
also with low intra-tumoural DPD expression was 26.3
(17.2–33.0) months compared to 22.3 (9.6–39.5) months in those
patients instead with high DPD expression, which was not
signiﬁcantly different (p = 0.360). The median (95% CI) overall
survival of patients treated with gemcitabine with low hENT1
intra-tumoural expression and also low DPD intra-tumoural
expression was 18.0 (7.6–15.3) months and 14.0 (9.1–15.7)
months for patients with low hENT1 and high DPD intra-
tumoural expression (p = 1.000).
Similarly, in patients with high hENT1 intra-tumoural expression
treated with 5FU/FA, there was no signiﬁcant difference between
those who also had high or low DPD intra-tumoural expression
with a median (95% CI) overall survival of 17.3 (0.6–38) and 26.0
(19.8–30.1) months respectively, (p = 1.000). However, in patients
with low hENT1 expression treated with 5FU/FA, intra-tumoural
DPD expression added signiﬁcant predictive value. Thus, patients
with low hENT1 and low DPD tumour expression treated with
5FU/FA had a median (95% CI) overall survival of 29.2 (19.5–41.9)
months compared to 9.7 (5.3–30.4) months in those with low
hENT1 and high DPD tumour expression (χ2LR = 9.28, p[raw] =
0.002, p[post Bonferroni correction] = 0.014).
DISCUSSION
In the present study, intra-tumoural DPD expression status was
analysed in the ESPAC-3(v2) population of patients with pancrea-
tic adenocarcinoma randomised to postoperative chemotherapy
with 5FU/FA or gemcitabine. Given the key role of DPD in the
catabolism of 5FU, we hypothesised that low intra-tumoural
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Fig. 1 Kaplan–Meier survival curves and median overall survival for DPD-low vs. DPD-high tumour expression in the entire chemotherapy-
treated population (5FU/FA plus gemcitabine), 5FU/FA treated patients, gemcitabine-treated patients, and the small observational (OBS)
population
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expression of DPD would result speciﬁcally in increased overall
survival in patients treated with 5FU/FU. We found that DPD
tumour expression was associated with reduced overall survival.
Intra-tumoural DPD expression was also signiﬁcant in the 5FU/FA
arm but not in the gemcitabine arm. As previously shown high
hENT1 tumour expression was associated with increased survival
in patients treated with gemcitabine but not in those treated with
5FU/FA.
Given the previously reported predictive value of hENT1 tumour
expression for adjuvant gemcitabine, we also explored the
potentially additional value of DPD tumour expression in those
high or low hENT1 intra-tumoural expression subgroups. In
patients with high hENT1 tumour expression treated with
gemcitabine, either low or high DPD expression showed a
favourable median overall survival. Similarly, in 5-FU/FA treated
patients with high hENT1 tumour expression no signiﬁcant
difference between high or low DPD tumour expression was
observed. This suggests that if hENT1 tumour expression is high,
evaluation of DPD tumour expression will not add any useful
information, and these patients should generally be recom-
mended for gemcitabine given a more tolerable toxicity proﬁle.
Another option, in situations where gemcitabine is unsuitable,
would be a 5FU/FA bolus regimen other than the Mayo Clinic
schedule or infusion regimen.
In patients with low hENT1 tumour expression treated with
gemcitabine, survival was poor irrespective of DPD tumour
expression. These data conﬁrm that hENT1 tumour expression is
a potentially useful predictive biomarker for improved survival
with adjuvant gemcitabine. However, for patients with low hENT1
tumour expression treated with 5FU/FA, evaluation of DPD tumour
expression provided additional predictive value. Patients with low
DPD tumour expression treated with 5FU/FA survived signiﬁcantly
longer than patients with high DPD tumour expression. This
suggests that there is a subgroup of patients with low hENT1
tumour expression and with low DPD tumour expression that
derive signiﬁcant survival beneﬁt from adjuvant 5FU/FA. Con-
versely, the subgroup of patients with hENT1-low tumour
expression and with high DPD tumour expression has a poor
survival outcome whether treated with 5FU/FA or gemcitabine.
We hypothesise that the additional prognostic information from
intra-tumoural DPD expression status could be integrated with the
hENT1 expression status to guide the selection of adjuvant
chemotherapy regimen. We can conclude the following.
1. Patients with high hENT1 tumour expression are likely to
derive a survival beneﬁt from gemcitabine therapy irrespec-
tive of DPD tumour expression status. Analysis of DPD
expression will not add any useful information.
2. In patients with low hENT1 tumour expression status,
gemcitabine is less efﬁcacious. For these patients DPD tumour
expression may be analysed for additional prognostic
information.
a. Patients with low hENT1 and low DPD tumour expres-
sion have a favourable prognosis with 5FU/FA treatment
(median overall survival = 29.2 months).
b. Patients with high hENT1 and high DPD tumour
expression have a poor prognosis whether given 5FU/
FA or gemcitabine (9.7 and 14 months median overall
survival, respectively). In these patients novel agents or
combination regimens may be needed to improve
survival.
Earlier studies investigating DPD tumour expression in
pancreatic cancer were performed in smaller and/or non-
controlled patient populations of Asian origin and involved the
use of S-1 and/or combination with gemcitabine or radio-
therapy.11,17–23 Asian individuals handle the metabolism ofT
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ﬂuoropyrimidines differently from Europeans in part due to
genotypic differences such as in CYP2A6 (which converts tegafur
in S-1 to 5FU.29) The present study provides novel evidence as it
was performed in a randomised controlled setting in patients
who were primarily of European origin, and notably receiving
single agent regimens.
Planned biomarker analyses of the ESPAC-4 population8 will
assess whether hENT1, DPD and/or other tumour expression
biomarker candidates are suitable for the identiﬁcation of patients
particularly beneﬁtting from the gemcitabine plus capecitabine
combination regimen. It is plausible that patients with low hENT1
and high DPD tumour expression may be resistant to gemcitabine
and 5FU/FA individually and to the gemcitabine/capecitabine
combination requiring alternative adjuvant strategies. If this is
conﬁrmed by biomarker analysis of the ESPAC4 trial biospecimens,
prospective trials of therapies acting independently of hENT1 and
DPD would be warranted in this population.
In conclusion, intra-tumoural DPD expression was a negative
prognostic biomarker for patients with pancreatic adenocarci-
noma undergoing postoperative chemotherapy. Intra-tumoural
hENT1 expression was conﬁrmed to be a predictive marker for
gemcitabine treatment, and the additional prognostic value of
DPD tumour expression may be used to estimate the survival in
patients with low hENT1 tumour expression, where low DPD
tumour expression indicates better prognosis at least for patients
treated with 5FU/FA. Patients with low hENT1 and high DPD
tumour expression present a particular challenge, and novel
agents and/or combination regimens will be needed to improve
survival for this subgroup.
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